Clinical trial
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
NCT00062127 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00062127 |
|---|---|
| Title | Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC616348) and Thalidomide (NSC66847) in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | irinotecan hydrochloride, thalidomide, pharmacological study |
| Enrollment | 35 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2006 |
| First posted | Jun 6, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: